{"organizations": [], "uuid": "b46a173dd195b6ecdcf2fce6fd50714d1dc90546", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alkermes-announces-fda-acceptance/brief-alkermes-announces-fda-acceptance-for-review-of-new-drug-application-for-alks-5461-idUSASC09VW3", "country": "US", "domain_rank": 408, "title": "BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T13:53:00.000+03:00", "replies_count": 0, "uuid": "b46a173dd195b6ecdcf2fce6fd50714d1dc90546"}, "author": "", "url": "https://www.reuters.com/article/brief-alkermes-announces-fda-acceptance/brief-alkermes-announces-fda-acceptance-for-review-of-new-drug-application-for-alks-5461-idUSASC09VW3", "ord_in_thread": 0, "title": "BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "fda acceptance for review", "sentiment": "negative"}, {"name": "alkermes plc", "sentiment": "none"}, {"name": "alkermes plc", "sentiment": "none"}, {"name": "alkermes", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "new drug application for alks 5461 reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16, 2018 / 10:53 AM / Updated 9 minutes ago BRIEF-Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461 Reuters Staff 1 Min Read \nApril 16 (Reuters) - Alkermes Plc: \n* ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER \n* ALKERMES PLC - FDA ACTION EXPECTED BY JAN. 31, 2019 \n* ALKERMES - ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-16T13:53:00.000+03:00", "crawled": "2018-04-16T14:06:38.000+03:00", "highlightTitle": ""}